Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioMérieux signs Clinton Foundation initiative on HIV
14 Januar, 2004
bioMérieux receives CE Mark certification for IVD products marketed in the European Union
08 Januar, 2004
bioMérieux has received CE Mark certifications for all of its in vitro diagnostic (IVD) products currently marketed in the European Union (EU). In compliance with the requirements of the 98/79/EC directive for CE Marking, which became applicable on December 7th, 2003, these certifications enable bioMérieux to continue to sell its products within the European Union after this date.
Cepheid and bioMérieux enter into strategic commercial program
06 Januar, 2004
bioMerieux to Apply Cepheid Platform Technology to NASBA Amplification Technology.